

29 September 2014

Market introduction of *CellLIVE*TM by MR Solutions, featuring Optiscan second generation platform.

MR Solutions (UK) has initiated market introduction of *CellLIVE*TM, a pre-clinical research imaging system based on Optiscan's second generation endomicroscopy platform.

The market introduction involves a range of activities including online marketing (www.mrsolutions.com/products/imaging-systems/confocal-microscopy), brochure distribution, introduction to MR Solutions international distribution network and incorporation of live system demonstration into the MR Solutions conference program, including the inaugural demonstration at the World Molecular Imaging Conference (WMIC) in Seoul, Korea this month.

Since partnering in February 2014, Optiscan and MR Solutions have worked closely to develop a powerful system dedicated to a targeted scientific market. Optiscan's second generation platform has enabled features not possible in its first generation predecessor, including full 3D imaging capabilities and seamless integration of advance analysis software.

Speaking after the successful market introduction at WMIC in Korea, David Taylor, chairman of MR Solutions said "We have been excited about this market introduction for some time but still have been pleasantly surprised with the interest and market reaction to the CellLIVE system". He also commented "We have been particularly impressed with the reaction from our distribution network who have been very excited about the prospects for sales in multiple regions - optical imaging is a major new growth area in our market space, and the CellLIVE is an impressive second generation system, at the right time to convert that opportunity".

Release of the product and commencement of sales is anticipated within approximately six months subject to completion of key tasks and required regulatory clearances. It should be noted that the *CellLIVE*TM is a research platform and not a medical device. Therefore no clinical trials or medical device approval submissions are required and the process is regarded by the company as low risk.

Further details and images are included in the following presentation material.



About Optiscan

Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan's unique and patented technologies enable high-powered microscopes to be miniaturised and used inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be achieved. Doctors can use the technology to instantly see cellular level details of tissue without the requirement to surgically remove tissue (biopsy).

Further information:

Gus Holt, Chairman Tel (613) 9538 3347 GusH@optiscan.com Bruce Andrew, CFO Tel (613) 9538 3398 brucea@optiscan.com






Unlocking the world of Live Micro Imaging (LMI) technology





solutions - pre-clinical imaging




- OEM / distribution agreement established February 2014
- MR Solutions specialises in small animal imaging technology
 - MRI, PET, SPECT, CT
- Optiscan technology adds optical microscopy, a key growth area for preclinical research
- Sept 2014 MR Solutions initiates market introduction of the new product – CellLIVETM
- See system at www.mrsolutions.com/pro ducts/imagingsystems/confocalmicroscopy






SOLUTIONS CellLIVETM - Key Features

Application Examples





MRS CellLIVE is a powerful, handheld fluorescence confocal endomicroscope imaging system that is designed specifically for in vivo research

- Based on Optiscan generation-2 platform
- Astounding ultra high resolution
- Full 3D capability
- Integrated scientific analysis software
- Other features:
 - Fast scanning for live tissue imaging
 - Small scanner for mouse imaging
 - Automation of Optiscan's unique depth actuation system enabling 3D imaging
 - High sensitivity for low level fluorescence
 - Spectral filtering for imaging multiple dyes
 - Advanced image processing and analysis
 - Instant 3d rendering and volumetric analysis
 - Integrated subject handling, monitoring, and temperature control.



CellLIVE[™] Market Introduction



- See CellLIVE[™] online at <u>www.mrsolutions.com/products/imaging-systems/confocal-microscopy</u>
- Production of a flyer for both digital and hardcopy circulation
- Introduction of the system to MR Solutions international distribution network.
- Conference exhibition
 - Inaugural display of the pre-release system at the WMIC South Korea
 - Working CellLIVE[™] system on display
 - Burst marketing to delegates
 - Flyer distribution
 - Incorporation in ongoing MR Solution conference exhibit plans
- MR Solutions now taking enquiries in leadup to formal product release



Market for pre-clinical imaging and MRS CellLIVE™

- Challenges and late stage failures of new therapies is driving preclinical research using in vivo models (whole animals)
- The pre-clinical imaging market was estimated at US\$800M in 2012
 with projected 14.5% annual growth for 5 years
- Two main forms of imaging:
 - Radiological PET,MRI, SPECT and CT
 - Optical whole body fluorescence and microscopy
- Whole body optical imaging now has a footprint of well over 1,000 instruments. Key limitations include artefacts due to low contrast and resolution, which drives the need for microscopy
- MR solutions product offerings include above radiological instruments, and now optical imaging
- The MRS CellLIVE[™] represents a key product offering to meet the growing need for optical microscopy as a pre-clinical imaging modality



News from the show floor (WMIC 2014)...

David Taylor, CEO and Chairman of MR Solutions said "We have been excited about this market introduction for some time but nonetheless have been pleasantly surprised with the interest and market reaction to the $CellLIVE^{TM}$ system".

"We have been particularly impressed with the reaction from our distribution network who have been excited about the prospects for sales in multiple regions".

"MR Solutions is experiencing strong growth in sales of its radiology product lines for small animal research. However, optical imaging is a major new growth area in our market space, and the $CellLIVE^{TM}$ is an impressive second generation product at the right time to convert that opportunity."



CellLIVETM Product Release

- The MRS CellLIVETM is a pre-clinical research product and not a medical device. No clinical trials or medical device approvals are required
- Optiscan holds appropriate certifications for release of the components of *CellLIVE*TM under the active OEM supply arrangement with MR Solutions
- There are a number of final specification refinements and engineering tasks required to progress to product release, but these are regarded by the company as low risk



